PharmaSGP Holding SE Holds Annual General Meeting 2025

PharmaSGP Holding SE convened its 2025 Annual General Meeting at its Gräfelfing headquarters, with 91.12% of share capital represented. The company reported a revenue increase of 17.5% in 2024, reaching €118.8 million, and an adjusted EBITDA growth of 9.2% to €37.2 million.

Despite an initial proposal for a €0.51 dividend per share, FUTRUE GmbH proposed and secured approval for a €0.05 dividend. This move aligns with a delisting offer, preserving the offer price of €28 per share without deductions.

The management confirmed a forecast for 2025, anticipating revenues between €122.0 million and €128.0 million, with an adjusted EBITDA forecast from €37.0 million to €39.0 million. In Q1 2025, revenues grew by 10.8% to €33.5 million, with a 4.0% increase in adjusted EBITDA.